NORA trial (GECP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).

Dolores Isla,M. Majem,M. Guirado,Bartomeu Massuti,Ramon De Las Penas,Ana Laura Ortega Granados,Manuel Domine,Raquel Marse Fabregat,Maria Angeles Sala Gonzalez,A. Paredes,Teresa Moran,Sergio Vázquez Estévez,Juan Coves,José Luis González Larriba,M Sánchez,D. Vicente,Núria Farré,Luis Fernández Fornós,F. Valcárcel,Mariano Provencio-Pulla

NORA trial (GECP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).

2018

8537Background: CT-RT is the standard treatment for unresectable LA-NSCLC. P plus vinorelbine is widely used. Metronomic CT is a frequent administration of low doses of CT. mOV has shown good effic...

Keywords:

Cell
Cisplatin
Pathology
Vinorelbine
Lung cancer
Oncology
Internal medicine
Medicine
Chemo-radiotherapy
Standard treatment
low doses
non small cell
locally advanced

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations